Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasmine Zain

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Blood|June 20, 2023
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockadeMatthew Mei, Lu Chen, James Godfrey, et al.
Blood|March 1, 2011
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaRichard L Piekarz, Robin Frye, H Miles Prince, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 4, 2023
Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell TherapyKyuwan Lee, Aleksi Iukuridze, Tianhui He, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaRichard L Piekarz, Robin Frye, Maria Turner, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 7, 2005
Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host diseaseFrancisco Lopez, Pablo Parker, Auayporn Nademanee, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2017
Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance RituximabMatthew G Mei, Thai M Cao, Lu Chen, et al.
Blood|July 9, 2005
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphomaAuayporn Nademanee, Stephen Forman, Arturo Molina, et al.
Blood Advances|February 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Blood Advances|December 3, 2021
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristicsMehdi Hamadani, Maud Ngoya, Anna Sureda, et al.
Blood|March 22, 2022
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICEMatthew G Mei, Hun Ju Lee, Joycelynne M Palmer, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Blood|June 20, 2023
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockadeMatthew Mei, Lu Chen, James Godfrey, et al.
Blood|March 1, 2011
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaRichard L Piekarz, Robin Frye, H Miles Prince, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 4, 2023
Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell TherapyKyuwan Lee, Aleksi Iukuridze, Tianhui He, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaRichard L Piekarz, Robin Frye, Maria Turner, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 7, 2005
Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host diseaseFrancisco Lopez, Pablo Parker, Auayporn Nademanee, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2017
Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance RituximabMatthew G Mei, Thai M Cao, Lu Chen, et al.
Blood|July 9, 2005
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphomaAuayporn Nademanee, Stephen Forman, Arturo Molina, et al.
Blood Advances|February 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Blood Advances|December 3, 2021
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristicsMehdi Hamadani, Maud Ngoya, Anna Sureda, et al.
Blood|March 22, 2022
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICEMatthew G Mei, Hun Ju Lee, Joycelynne M Palmer, et al.
Pageof 10